TRC101

DRUG4 trials

Sponsors

Tricida, Inc.

Conditions

AcidosisChronic Kidney DiseaseMetabolic Acidosis

Phase 1

Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

CompletedNCT02809183

Tricida, Inc.Acidosis

Start: 2016-03-31End: 2016-11-30Updated: 2020-01-14

Phase 3

Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

CompletedNCT03317444

Tricida, Inc.Metabolic Acidosis

Start: 2017-09-26End: 2018-05-15Updated: 2021-04-26

Long-term Safety Extension to Study TRCA-301

CompletedNCT03390842

Tricida, Inc.Metabolic Acidosis

Start: 2017-12-20End: 2019-02-22Updated: 2021-10-22

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

TerminatedNCT03710291

Tricida, Inc.Chronic Kidney Disease, Metabolic Acidosis

Start: 2018-11-20End: 2022-09-27Updated: 2022-10-14

Related Papers

VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

Journal of the American Society of Nephrology2024-01-2313 citations

Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial

BMC Nephrology2022-02-255 citations

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.

2019-06-2464 citations

Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.

2019-03-0857 citations